

13. Kyrle PA, Kammer M, Eischer L et al. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. *J Thromb Haemost.* 2016;14(12):2402-2409.
14. Jiménez D, Díaz G, Marín E et al. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. *Thromb Haemost.* 2006;95(3):562-566.
15. Kearon C. Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated. *J Thromb Thrombolysis.* 2011;31(3):295-300.
16. Barco S, Corti M, Trinchero A et al. Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. *J Thromb Haemost.* 2017;15(7):1436-1442.
17. Rosendaal F. Venous thrombosis: a multicausal disease. *Lancet.* 1999;353:1167-1173.
18. Margaglione M, Grandone E. Population genetics of venous thromboembolism. A narrative review. *Thromb Haemost.* 2011;105(2):221-31.
19. Zöller B, Li X, Ohlsson H et al. Family history of venous thromboembolism as a risk factor and genetic research tool. *Thromb Haemost.* 2015;114(5):890-900.
20. Mannucci PM, Franchini M. Classic thrombophilic gene variants. *Thromb Haemost.* 2015;114(5):885-9.
21. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. *Thromb Diath Haemorrh.* 1965;13:516-530.
22. Griffin JH, Evatt B, Zimmerman TS et al. Deficiency of protein C in congenital thrombotic disease. *J Clin Invest.* 1981;68:1370-1373.
23. Schwartz HP, Fisher M, Hopmeier P et al. Plasma protein S deficiency in familial thrombotic disease. *Blood.* 1984;64:1297-1300.
24. Giri TK, Yamazaki T, Sala N et al. Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. *Blood.* 2000;96:523-531.
25. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature.* 1994;369:64-67.
26. Poort SR, Rosendaal FR, Reitsma PH et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood.* 1996;88:3698-3703.
27. Manderstedt E, Lind-Halldén C, Halldén C et al. Classic thrombophilias and thrombotic risk among middle-aged and older adults: a population-based cohort study. *J Am Heart Assoc.* 2022;11(4):e023018. DOI: 10.1161/JAHA.121.023018.

28. Manolio TA: Genomewide association studies and assessment of the risk of disease. *N Engl J Med.* 2010;363:166-76.
29. Bezemer ID, Bare LA, Doggen CJ et al. Gene variants associated with deep vein thrombosis. *JAMA.* 2008; 299:1306-1314.
30. Trégouët DA, Heath S, Saut N et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. *Blood.* 2009;113(21):5298-5303.
31. Tang W, Teichert M, Chasman DI et al. A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. *Genet Epidemiol.* 2013;37(5):512-521.
32. Lindström S, Wang L, Smith EN et al. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. *Blood.* 2019;134(19):1645-1657.
33. Klarin D, Busenell E, Judy R et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. *Nat Genet.* 2019;51(11):1574-1579.
34. Zöller B, Svensson PJ, Dahlbäck B et al. Genetic risk factors for venous thromboembolism. *Expert Rev Hematol.* 2020;13(9):971-981.
35. Vrtel P, Slavik L, Vodicka R et al. Detection of unknown and rare pathogenic variants in antithrombin, protein C and protein S deficiency using high-throughput targeted sequencing. *Diagnostics (Basel)* 2022;12(5):1060. DOI: 10.3390/diagnostics12051060.
36. de Haan HG, Bezemer ID, Doggen CJ et al. Multiple SNP testing improves risk prediction of first venous thrombosis. *Blood.* 2012;120(3):656-663.
37. van Hylckama Vlieg A, Flinterman LE, Bare LA et al. Genetic variations associated with recurrent venous thrombosis. *Circ Cardiovasc Genet.* 2014;7(6):806-13.
38. Kolin DA, Kulm S, Elemento O. Prediction of primary venous thromboembolism based on clinical and genetic factors within the U.K. Biobank. *Sci Rep.* 2021;11(1):21340. Erratum in: *Sci Rep.* 2021;11(1):23364.
39. Clifton L, Collister JA, Liu X et al. Assessing agreement between different polygenic risk scores in the UK Biobank. *Sci Rep.* 2022;12(1):12812.
40. Choi SW, Mak TS, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. *Nat Protoc.* 2020;15(9):2759-2772.

Předplatné časopisu

Vnitřní lékařství

ROČNÍK 69

2023

OBJEDNÁVEJTE

www.casopisvnitrnilekarstvi.cz
předplatne@solen.cz



TIŠTĚNÝ ČASOPIS

8 čísel / rok



ROZŠÍŘENÁ E-VERZE

na www.casopisvnitrnilekarstvi.cz



SUPPLEMENTA
A ODBORNÉ PUBLIKACE

Už máte předplaceno?



S předplatným časopisem Vnitřní lékařství na rok 2023 získáte nárok na **50% slevu** z registračního poplatku na nový kongres **Diabetologie pro praxi** (26. 1. 2023 v Olomouci).

www.diabetologiepropraxi.cz



FANDÍME MLADÝM LÉKAŘŮM,
a proto předplatitelé do 35 let získají **50% SLEUVU**



Spojili jsme síly
Interní medicína pro praxi
a Vnitřní lékařství
pod jednou hlavičkou